Publications by authors named "D Babic-Naglic"
Erratum to: The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology.
Rheumatol Int
August 2017
The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology.
Rheumatol Int
August 2017
The aim of this study was to establish consensus for potential early symptomatic knee osteoarthritis (ESKOA) clinical definition and referral criteria from primary care to rheumatologists, based on available data from literature and a qualitative approach, in order to perform studies on patients fulfilling such criteria and to validate the obtained ESKOA definition. A complex methodological approach was followed including: (1) three focus groups (FG), including expert clinicians, researchers and patients; (2) a systematic literature review (SLR); (3) two discussion groups followed by a Delphi survey. FG and SLR were performed in parallel to inform discussion groups in order to identify relevant constructs to be included in the modified Delphi survey.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to determine if rheumatoid arthritis (RA) patients have a higher prevalence of metabolic syndrome (MetS) compared to osteoarthritis (OA) patients, linking it to higher chronic inflammation levels in RA.
- Findings revealed that OA patients had a 1.6-fold higher prevalence of MetS, with greater waist circumference, systolic blood pressure, fasting blood glucose, and triglycerides than RA patients, while some measures were similar between both groups.
- Multivariate analysis indicated that OA type, age, and ESR levels were significant predictors of MetS, suggesting an increased risk for OA patients potentially linked to a shared underlying cause.
Golimumab is a human monoclonal antibody which inhibits tumor necrosis factor-alpha (TNF-α) and is approved for the treatment of inflammatory arthritides (rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis) when the conventional non-pharmacological and pharmacological therapies fail to cause remission or low disease activity. In this retrospective study there were included patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis who were treated in Croatia with golimumab, from June 2011 to June 2013. included and these retrospective data are compared with similar data from clinical trials and other available databases.
View Article and Find Full Text PDFToday, the goal of the treatment of rheumatoid arthritis is remission of disease activity which should be achieved through the first 6 months of treatment with conventional disease modifying antirheumatic drugs and tight control principle. The treatment must be adjusted to the state of disease on each visit. In the absence of remission or low disease activity biological drugs are indicated.
View Article and Find Full Text PDF